Pfizer Inc. $PFE Shares Bought by Fifth Third Bancorp

Posted by Brian Himes on Jul 12th, 2026

Fifth Third Bancorp lifted its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 75.1% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,536,233 shares of the biopharmaceutical company’s stock after purchasing an additional 1,945,958 shares during the quarter. Fifth Third Bancorp’s holdings in Pfizer were worth $127,377,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Vermillion Wealth Management Inc. increased its stake in Pfizer by 19.4% during the 1st quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company’s stock valued at $66,000 after buying an additional 382 shares during the period. Triad Wealth Partners LLC boosted its holdings in shares of Pfizer by 1.9% in the fourth quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock valued at $510,000 after acquiring an additional 386 shares in the last quarter. Eagle Capital Management LLC raised its holdings in Pfizer by 0.3% during the first quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company’s stock worth $3,554,000 after purchasing an additional 390 shares in the last quarter. ETF Store Inc. lifted its position in Pfizer by 3.8% in the fourth quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock worth $272,000 after purchasing an additional 396 shares during the period. Finally, Mattern Wealth Management LLC increased its position in shares of Pfizer by 4.6% during the 4th quarter. Mattern Wealth Management LLC now owns 9,161 shares of the biopharmaceutical company’s stock valued at $228,000 after purchasing an additional 400 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

Positive Sentiment: The U.S. FDA approved PADCEV plus Keytruda for muscle-invasive bladder cancer, expanding the label for a key Pfizer/Astellas regimen and potentially opening the door to more sales in oncology. Article: U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
Positive Sentiment: Pfizer’s oncology story also got incremental attention from a completed lorlatinib lung cancer study and other clinical updates, which keep investors focused on the company’s pipeline rather than only its mature products. Article: Pfizer’s Lorlatinib Lung Cancer Study Wraps Up, Offering Fresh Signals for PFE Investors
Neutral Sentiment: Bank of America lowered its price target on Pfizer to $26 from $27 while keeping a neutral rating, signaling limited upside but no major change in its overall stance. Article: Pfizer had its price target lowered by Bank of America Corporation from $27.00 to $26.00.
Negative Sentiment: Several market commentary pieces highlighted concerns about Pfizer’s growth outlook and mixed second-quarter expectations, including skepticism about how quickly Seagen-related benefits will show up in results. Article: Pfizer Poised for Mixed Second Quarter, RBC Says

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. Citigroup raised their target price on Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research note on Wednesday, April 29th. Guggenheim lifted their price objective on shares of Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a research note on Tuesday, March 24th. Royal Bank Of Canada upgraded shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price on the stock in a report on Tuesday, June 9th. JPMorgan Chase & Co. reduced their target price on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a report on Wednesday. Finally, Morgan Stanley increased their price objective on Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a research report on Friday, April 10th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Pfizer has a consensus rating of “Hold” and a consensus target price of $28.56.

Check Out Our Latest Research Report on Pfizer

Pfizer Trading Down 0.1%

Pfizer stock traded down $0.04 during midday trading on Friday, reaching $24.21. The stock had a trading volume of 27,476,453 shares, compared to its average volume of 47,734,172. Pfizer Inc. has a twelve month low of $23.11 and a twelve month high of $28.75. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. The firm has a market cap of $138.01 billion, a price-to-earnings ratio of 18.48 and a beta of 0.35. The firm’s fifty day simple moving average is $25.37 and its two-hundred day simple moving average is $26.18.

Pfizer (NYSE:PFE – Get Free Report) last released its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company had revenue of $14.45 billion during the quarter, compared to analyst estimates of $13.84 billion. During the same quarter in the prior year, the company earned $0.92 earnings per share. The company’s revenue for the quarter was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.1%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s payout ratio is 131.30%.

About Pfizer

(Free Report)

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.